Genitourinary Drugs Market Size, Share & Industry Analysis By Drug Class (Androgen Receptor Pathway Inhibitors, GnRH Agonists/GnRH Antagonists, and Others), By Disease Indication (Prostate Cancer, Benign Prostatic Hyperplasia (BPH), Erectile Dysfunction, and Others), By Age Group (Pediatric, Adult, and others), By Type (Branded and Generics), By Route of Administration (Oral, Vaginal, Injectable/Parenteral, Topical/Transdermal, and Others), By Gender (Male and Female), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Others), and Regional Forecast, 2026-2034

Last Updated: May 08, 2026 | Format: PDF | Report ID: FBI116092

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2021-2034
Base Year	2025
Estimated Year	2026
Forecast Period	2026-2034
Historical Period	2021-2024
Growth Rate	CAGR of 4.98% from 2026 to 2034
Unit	Value (USD Billion)
Segmentation	By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Gender, Distribution Channel, and Region
By Drug Class	Androgen Receptor Pathway Inhibitors GnRH Agonists/GnRH Antagonists PDE5 Inhibitors Alpha Blockers Antimuscarinics/Anticholinergics Beta-3 Adrenergic Agonists Others
By Disease Indication	Prostate Cancer Benign Prostatic Hyperplasia (BPH) Erectile Dysfunction Overactive Bladder (OAB) Urinary Tract Infections (UTIs) Bladder/Urothelial Cancer Others
By Age Group	Pediatric Adult Geriatric
By Type	Branded Generics
By Route of Administration	Oral Vaginal Injectable/Parenteral Topical/Transdermal Others
By Gender	Male Female
By Distribution Channel	Hospital Pharmacies Drug Stores & Retail Pharmacies Online Pharmacies Specialty Pharmacies
By Region	North America (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Gender, Distribution Channel, and Country) U.S. Canada Europe (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Gender, Distribution Channel, and Country/Sub-region) Germany U.K. France Spain Italy Scandinavia Rest of Europe Asia Pacific (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Gender, Distribution Channel, and Country/Sub-region) China Japan India Australia Southeast Asia Rest of Asia Pacific Latin America (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Gender, Distribution Channel, and Country/Sub-region) Brazil Mexico Rest of Latin America Middle East & Africa (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Gender, Distribution Channel, and Country/Sub-region) GCC South Africa Rest of the Middle East & Africa